September 22, 2022 7:41am

With Q3 ending in seven (7) sessions … make sure your investments are on a static line before any portfolio jump

Indications: 3 Negative and 2 Positive Indications with 1 Pump/Promote (BSTG – the usual suspect)

The cell and gene therapy sector shows more signs of downside movement alternating to continued weakness.

No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.19% or (-57 points), S&P futures are DOWN -0.32% (-12 points) and NASDAQ futures are DOWN -0.49% (-57 points) early in the pre-open – so far,


U.S. stock futures slightly higher on Thursday morning following a big decline after Fed policy announcement,

European markets dive as the Swiss National Bank on Thursday raised its benchmark interest rate to 0.5%, a shift that brings an end to an era of negative rates in Europe,

Asian Pacific markets sank as Japan’s central bank intervened keeping interest rates unchanged, in line with expectations.



Wednesday was a volatile session in the major averages as traders weighed-in another rate hike from the Fed.

The Dow closed DOWN -522.45 points (-1.70%) the S&P closed DOWN -66.00 points (-1.71%) while the Nasdaq closed DOWN -204.86 points (-1.79%)

Reiterating, On-target quote, “Stocks are finally coming around to the idea that the Federal Reserve is willing to push the economy into a recession to tame inflation, according to Chris Zaccarelli, chief investment officer of Independent Advisor Alliance.” <CNBC>

Economic Data Docket: weekly jobless claims is expected at 8:30 a.m. ET.


RegMed Investors’ (RMi) closing bell: “as expected, 0.75 percentage or basis points, let’s be done with the discourse; inflation is NOT going away! Investors feel the pain, as confidence and conviction continue to drop. The lack of capital market access will be debilitating and G&A cut-back factor.” …


Ebb and flow:

Q3/22 – September – 1 holiday, 7 positive and 7 negative closes

•             August – 1 neutral, 11 positive and 11 negative closes

•             July - 1 holiday, 10 negative and 10 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indication:

Alnylam Pharmaceuticals (ALNY) closed down -$5.62 to $206.39 with a negative -$5.49 or -2.66% pre-open indication,

Chinook Therapeutics (KDNY) closed down -40.48 to $19,96 with a negative -$0.20 or -1% pre-open indication,

Verve Therapeutics (VERV) closed up +$0.06 to $35.58 after Tuesday’s $0.11 and Monday’s -$0.92, Friday’s -$4.94 and Thursday’s +$1.14 with a negative -$0.18 or -0.51% pre-open indication.


Positive Indication:

Sangamo Therapeutics (SGMO) closed down -$0.23 to $5.07 with a positive +$0.06 or +1.18% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$3.48 to $66.65 with a positive +$0.40 or +0.60% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed FLAT with 3,196 sha5res traded after Tuesday’s +$0.10 with 9,718 shares traded, Friday’s +$1.19 with 2,660 shares traded and last Thursday’s -$0.19 with 717 shares traded following the previous Wednesday’s +$0.15 with 2,101 shares traded, Tuesday’s -$0.30 with 500 shares traded and last Monday’s -$0.10 with 442 shares traded <3-month average = 1,806>,

Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?

  • How many non-citizens of Chinese nationality are employed at BSTG – 3 managers/directors of 5 and 3 of 5 board directors?
  • Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
  • What is DST Capital?  Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG?  Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
  • Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?


The BOTTOM LINE: The Fed policy announcement will hurt some portfolios:  as I had been writing, it's a time for investors to have minimal exposure.

Especially with another quarter (Q3) about to close … and then back to earnings season – that’s LPS (loss-per-share) period!

I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!

When a cell and gene therapy sector equity sells-off to or below a buy point, investors face a tough decision: hold tight, exit or trim the position. There's not necessarily a "right" answer.

Sometimes the stock will bounce right back, others will keep falling — perhaps after briefly bouncing. A more-cautious approach may make more sense in the current volatile market.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash? Start by looking at cell and gene therapy companies trading below cash!” 

When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.

As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”

That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.